Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 10:20 ET | Source: Spherix Global Insights

The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market

EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
November 15, 2023 11:22 ET | Source: Spherix Global Insights

Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
November 13, 2023 09:22 ET | Source: Spherix Global Insights

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
May 04, 2022 16:53 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...
April 30, 2022 11:48 ET | Source: The Rosen Law Firm PA

ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABBV

NEW YORK, April 30, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
April 20, 2022 10:28 ET | Source: The Rosen Law Firm PA

ABBV LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
April 09, 2022 15:06 ET | Source: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV

NEW YORK, April 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...